Drug Search Results
More Filters [+]

Candesartan

Alternative Names: candesartan, blopress, atacand, atacand hct
Latest Update: 2024-12-06
Latest Update Note: Clinical Trial Update

Product Description

Candesartan is used alone or together with other medicines to treat high blood pressure (hypertension) in adults and children 1 to 16 years of age. High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. Lowering blood pressure can reduce the risk of strokes and heart attacks. Candesartan is also used to treat heart failure in adults and cut down on the number of hospital visits for heart problems. Candesartan is an angiotensin II receptor blocker (ARB). It works by blocking the action of a substance in the body that causes the blood vessels to tighten. As a result, candesartan relaxes the blood vessels. (Sourced from: https://www.mayoclinic.org/drugs-supplements/candesartan-oral-route/side-effects/drg-20068192?p=1)

Mechanisms of Action: AT1 Antagonist,ARB Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Candesartan

Countries in Clinic: Australia, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, United Kingdom, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: COVID-19|Cardiomyopathy, Dilated|Hypercholesterolemia|Hypertension|Influenza, Human|Pneumonia

Phase 2: Migraine Disorders|Migraine with Aura|Migraine without Aura

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

EARLY-GENE

P3

Active, not recruiting

Cardiomyopathy, Dilated

2026-03-09

REMAP-CAP

P3

Recruiting

Influenza, Human|COVID-19|Pneumonia

2026-02-01

HODO-2224

P3

Not yet recruiting

Hypertension|Hypercholesterolemia

2025-04-15

OPTION TREAT

P3

Recruiting

Hypertension

2023-12-31

Recent News Events